Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in Alabama: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Phase 3 Recruiting Network
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in Alabama: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Alabama: - USA Mitchell Cancer Institute ( Site 0014) — Mobile, Alabama
Phase 3 Recruiting Industry
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Sponsor: Priothera SAS
NCT ID: NCT05429632
Sites in Alabama: - University of Alabama Hospital (UAB Hospital) — Birmingham, Alabama
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554406
Sites in Alabama: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Alabama: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Alabama: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
Phase 2 Recruiting Academic/Other
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hemato…
Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
NCT ID: NCT03509961
Sites in Alabama: - Children's of Alabama/University of Alabama in Birmingham(UAB) — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Industry
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/r…
Sponsor: Sellas Life Sciences Group
NCT ID: NCT04588922
Sites in Alabama: - O'Neal Comprehensive Cancer Center, University of Alabama — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Industry
The goal of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TERN-701, a highly selective allosteric inhibitor of BCR-ABL1, in participants with previously treated chronic phase - chroni…
Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT ID: NCT06163430
Sites in Alabama: - University of Alabama Medicine (UAB Medicine) — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimization study of surovatamig (AZD0486) to evaluate the safety, tolerability, and efficacy of surovatamig (AZD0486) monotherapy in participants w…
Sponsor: AstraZeneca
NCT ID: NCT06137118
Sites in Alabama: - Research Site — Birmingham, Alabama
Phase 2 Recruiting Academic/Other
The purpose of this study is to test whether the combination of the drugs called tacrolimus (Tac), methotrexate (MTX) and new dosing strategy of another drug called (rabbit Anti-thymocyte Globulin \[ATG\]) will help prevent the development…
Sponsor: University of Alabama at Birmingham
NCT ID: NCT06315309
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Industry
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or bla…
Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT04260022
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
EARLY Phase 1 Recruiting Academic/Other
Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymph…
Sponsor: New York Medical College
NCT ID: NCT03719105
Sites in Alabama: - University of Alabama — Birmingham, Alabama
Phase 1 Recruiting Academic/Other
The purpose of this study is to determine the safety of adding Decitabine and Venetoclax to patients undergoing reduced intensity allogenic transplantation for treatment of hematologic malignances with Fludarabine and Melphalan.
Sponsor: University of Alabama at Birmingham
NCT ID: NCT07044544
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Recruiting Network
This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increased risk for side effects during treatment for acute leukemia, but it is unclear …
Sponsor: Children's Oncology Group
NCT ID: NCT05702645
Sites in Alabama: - Children's Hospital of Alabama — Birmingham, Alabama
Recruiting Industry
This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
Sponsor: Blueprint Medicines Corporation
NCT ID: NCT07143669
Sites in Alabama: - AllerVie Clinical Research — Birmingham, Alabama
- O'Neal Comprehensive Cancer Center at the UAB — Birmingham, Alabama
NA Recruiting Academic/Other
This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukem…
Sponsor: Massachusetts General Hospital
NCT ID: NCT05237258
Sites in Alabama: - University of Alabama - Birmingham — Birmingham, Alabama
Recruiting Industry
This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for 1L and 2L,…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT07091019
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Recruiting Industry
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our b…
Sponsor: Ossium Health, Inc.
NCT ID: NCT07145411
Sites in Alabama: - University of Alabama, Birmingham — Birmingham, Alabama
Recruiting Academic/Other
The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients age…
Sponsor: University of Alabama at Birmingham
NCT ID: NCT05556928
Sites in Alabama: - Kirklin Clinic of UAB Hospital — Birmingham, Alabama